Developer docs
API playgroundTry for free, no card

Search company profiles

Dechra

Full company profile

uuid000crwc

Namestring
Dechra
Legal namestring
Dechra Pharmaceuticals Limited
Websiteurl
dechra.co.uk
Company typeenum
Public
Founded yearint
1997
Descriptiontext

Dechra is a global specialist veterinary pharmaceuticals company founded in 1997 and publicly listed on the London Stock Exchange under ticker DCH. The company develops, manufactures, and distributes prescription-only pharmaceutical products across four primary animal segments: companion animals (dogs and cats), equine, food-producing animals (cattle, pigs, poultry), and exotics. Its portfolio spans 250+ SKUs covering endocrinology, anesthesia and analgesia, dermatology, anti-infectives, fluid therapy, nutrition, and vaccines, with category-defining products including Vetoryl (trilostane for canine Cushing's disease), CosACTHen (cosyntropin for canine adrenal function testing), Zygolide (pergolide for equine PPID), and Emeprev (maropitant citrate injectable).

The business model is B2B enterprise field sales targeted at licensed veterinarians, veterinary surgeons, and veterinary nurses, with distribution through veterinary practices, wholesale distributors, and selected online pharmacies. Pricing is not publicly disclosed and operates on a per-product prescription basis. Dechra monetizes through one-time product sales across more than 50 countries, supported by country-specific localized websites and the Dechra Academy eLearning platform that delivers free CPD modules and educational content to veterinary professionals.

The company is executing an aggressive inorganic growth strategy, having deployed over $990 million in disclosed acquisition spend since 2022 across Piedmont ($210M), Invetx ($520M), a US manufacturer ($260M), and veterinary insulin programs from Akston Biosciences. It is simultaneously relocating its global headquarters from Northwich, England to Boston, Massachusetts by June 2026 to consolidate US operations and position itself as a transatlantic bridge. Regulatory momentum is strong, with three FDA approvals secured between December 2025 and May 2026 across canine, feline, and equine indications.

Short descriptiontext

Dechra is a publicly listed global specialist veterinary pharmaceuticals company that develops, manufactures, and distributes 250+ prescription drugs for companion animals, equine, food-producing animals, and exotics, selling directly to veterinarians and distributors across more than 50 countries.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersShrewsbury, United Kingdom
HQ citystring
Shrewsbury
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary pharmaceuticals, companion animal medicine, equine pharmaceuticals, livestock medications, animal health products
Industry4 codes
PRIMARYHLAMAEAG
Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAH
Dermatology & Allergy Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Veterinary Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Veterinary Pharmaceutical Products
TypeOne Time License
Description

Dechra generates revenue through the sale of prescription and non-prescription veterinary pharmaceutical products across multiple animal categories including companion animals (dogs, cats), equine, food-producing animals (cattle, pigs, poultry), and exotics. Products include treatments for endocrinology, anesthesia, analgesia, dermatology, anti-infectives, fluid therapy, and nutrition.

dechra.co.uk
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1CosACTHen
Description

Cosyntropin injection for canine patients - first FDA-approved cosyntropin specifically indicated for canine patients for ACTH stimulation testing

prnewswire.com
+8 more records
Core offering1 text field

Dechra develops, manufactures, and sells prescription and non-prescription veterinary pharmaceutical products across companion animals (dogs, cats), equine (horses), food-producing animals (cattle, pigs, poultry), and exotics. The portfolio spans therapeutic areas including endocrinology, anesthesia and analgesia, dermatology, anti-infectives, fluid therapy, nutrition, and vaccines. Dechra also provides the Dechra Academy eLearning platform offering free CPD modules and educational content to veterinary professionals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Human Animal Bond Certified Company recognition in 2025
+1 more record
Product and service10 records
1CosACTHen (cosyntropin injection)
CategoryEndocrinology
2Zygolide (pergolide tablets)
CategoryEndocrinology
3Emeprev Injectable Solution (maropitant citrate)
CategoryAnti-emetic / Internal Medicine
4Felimazole Liquid
CategoryEndocrinology
5Furosoral
CategoryCardiovascular / Diuretic
6Lodisure (amlodipine)
CategoryCardiovascular
7Vetoryl (trilostane)
CategoryEndocrinology
Description

Trilostane capsules and tablets for the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease and syndrome) in dogs. Available in multiple dosages (5mg, 10mg, 20mg, 30mg, 60mg, 120mg) and formulations including hard capsules and flavored tablets.

8Diatrim (sulfadiazine/trimethoprim solution for injection)
CategoryAnti-infectives
Description

Sulfadiazine/trimethoprim solution for injection indicated for use in cattle, pigs, dogs, and cats.

9Cyclo Spray (chlortetracycline topical spray)
CategoryAnti-infectives / Topical
Description

Chlortetracycline topical spray for superficial wound infections in livestock.

10TAF Spray (thiamphenicol cutaneous spray)
CategoryAnti-infectives / Topical
Description

Thiamphenicol cutaneous spray for wound infections in animals.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-01-24
Description

Intervacc received orders from Dechra Pharmaceuticals with an order value equivalent to approximately SEK 5.8 million, indicating a supply relationship.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-07-19
Description

Latham & Watkins advised Invetx in connection with its acquisition by Dechra Pharmaceuticals, providing legal advisory services for the $520 million transaction.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

France-based global veterinary pharmaceutical company, one of the top independent vet pharma specialists after Zoetis. Direct peer in companion animal specialty therapeutics, including in endocrinology (Vetoryl competitor in Cushing's) and dermatology.

TypeDirect peer
Description

Major US-listed animal health company (formerly Eli Lilly's animal health division, plus Bayer Animal Health acquisition). Competes head-to-head with Dechra in companion animal endocrinology, dermatology, and livestock therapeutics. Direct overlap in therapeutic areas and geographic channels.

TypeDirect peer
Description

The world's largest pure-play animal health company. Sells companion animal and livestock pharmaceuticals across endocrinology, dermatology, vaccines, and parasiticides. Direct competitor to Dechra across most therapeutic categories and the dominant benchmark for vet pharma economics.

TypeDirect peer
Description

US-listed animal health and nutrition company focused on livestock (poultry vaccines, nutritional specialty products, parasiticides) and select companion animal products. Most directly comparable on Dechra's food-producing animal side (poultry vaccines, cattle therapeutics).

TypeOthers
Description

Leading veterinary diagnostics company rather than pharma, but operates in the same veterinary clinic channel and benefits from the same secular pet care tailwinds. Comparable unit economics and channel exposure make it the natural reference for the companion animal vet services ecosystem Dechra sells into, even though it doesn't directly compete on therapeutics.

TypeDirect peer
Description

Independent French veterinary pharmaceutical company competing in companion animal endocrinology (notably Prilactone/Trilostane in Cushing's disease) and dermatology. Direct head-to-head competitor to Dechra's Vetoryl franchise in key European markets.

TypeDirect peer
Description

UK/Northern Ireland-based privately held veterinary pharmaceutical manufacturer. Comparable as a fellow non-US-headquartered vet pharma specialist operating in anti-infectives, parasiticides, and production animal therapeutics; competes with Dechra in European livestock channels.

TypeBroad incumbent
Description

Animal health division of Merck/MSD, one of the largest global players in livestock vaccines and parasiticides. Overlaps with Dechra's food-producing animal segment while operating as a broader human-pharma-backed incumbent.

9Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

Top-3 global animal health player owned by Boehringer Ingelheim (acquired Merial). Competes with Dechra across therapeutic areas and vaccines as part of a broader human-pharma-supported portfolio rather than as a pure-play specialist.

TypeDirect peer
Description

French global veterinary pharmaceutical company with strong positions in vaccines, companion animal therapeutics, and livestock. Direct competitor in food-producing animal segment (mastitis, vaccines, parasiticides) where Dechra also operates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dechra

Veterinary Pharmaceuticalsdechra.co.uk

Dechra is a publicly listed global specialist veterinary pharmaceuticals company that develops, manufactures, and distributes 250+ prescription drugs for companion animals, equine, food-producing animals, and exotics, selling directly to veterinarians and distributors across more than 50 countries.

What Dechra does

Dechra is a global specialist veterinary pharmaceuticals company founded in 1997 and publicly listed on the London Stock Exchange under ticker DCH. The company develops, manufactures, and distributes prescription-only pharmaceutical products across four primary animal segments: companion animals (dogs and cats), equine, food-producing animals (cattle, pigs, poultry), and exotics. Its portfolio spans 250+ SKUs covering endocrinology, anesthesia and analgesia, dermatology, anti-infectives, fluid therapy, nutrition, and vaccines, with category-defining products including Vetoryl (trilostane for canine Cushing's disease), CosACTHen (cosyntropin for canine adrenal function testing), Zygolide (pergolide for equine PPID), and Emeprev (maropitant citrate injectable).

The business model is B2B enterprise field sales targeted at licensed veterinarians, veterinary surgeons, and veterinary nurses, with distribution through veterinary practices, wholesale distributors, and selected online pharmacies. Pricing is not publicly disclosed and operates on a per-product prescription basis. Dechra monetizes through one-time product sales across more than 50 countries, supported by country-specific localized websites and the Dechra Academy eLearning platform that delivers free CPD modules and educational content to veterinary professionals.

The company is executing an aggressive inorganic growth strategy, having deployed over $990 million in disclosed acquisition spend since 2022 across Piedmont ($210M), Invetx ($520M), a US manufacturer ($260M), and veterinary insulin programs from Akston Biosciences. It is simultaneously relocating its global headquarters from Northwich, England to Boston, Massachusetts by June 2026 to consolidate US operations and position itself as a transatlantic bridge. Regulatory momentum is strong, with three FDA approvals secured between December 2025 and May 2026 across canine, feline, and equine indications.

Dechra firmographics

Firmographics
Name
Dechra
Legal name
Dechra Pharmaceuticals Limited
Website
https://dechra.co.uk
Company type
Public
Founded year
1997
Operating status
Operating
Short description
Dechra is a publicly listed global specialist veterinary pharmaceuticals company that develops, manufactures, and distributes 250+ prescription drugs for companion animals, equine, food-producing animals, and exotics, selling directly to veterinarians and distributors across more than 50 countries.
Ownership category
akta.pro rank

Dechra industry classification

Industry
Product category
Veterinary Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMAEAG
Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAH
Dermatology & Allergy Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services

Keywords

  • Veterinary pharmaceuticals
  • Companion animal medicine
  • Equine pharmaceuticals
  • Livestock medications
  • Animal health products

Where Dechra is headquartered

Location

Headquarters

HQ city
Shrewsbury
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Dechra business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. Veterinary Pharmaceutical Products: Dechra generates revenue through the sale of prescription and non-prescription veterinary pharmaceutical products across multiple animal categories including companion animals (dogs, cats), equine, food-producing animals (cattle, pigs, poultry), and exotics. Products include treatments for endocrinology, anesthesia, analgesia, dermatology, anti-infectives, fluid therapy, and nutrition.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Dechra product offering

Product offering

Core offering

Dechra develops, manufactures, and sells prescription and non-prescription veterinary pharmaceutical products across companion animals (dogs, cats), equine (horses), food-producing animals (cattle, pigs, poultry), and exotics. The portfolio spans therapeutic areas including endocrinology, anesthesia and analgesia, dermatology, anti-infectives, fluid therapy, nutrition, and vaccines. Dechra also provides the Dechra Academy eLearning platform offering free CPD modules and educational content to veterinary professionals.

Differentiator

Problem solved

Functional benefit

Brands

  • CosACTHen: Cosyntropin injection for canine patients - first FDA-approved cosyntropin specifically indicated for canine patients for ACTH stimulation testing
  • Zygolide
  • Emeprev
  • Lodisure
  • Furosoral
  • Vetoryl
  • Diatrim
  • Cyclo Spray
  • TAF Spray

Products and services

  • CosACTHen (cosyntropin injection)
  • Zygolide (pergolide tablets)
  • Emeprev Injectable Solution (maropitant citrate)
  • Felimazole Liquid
  • Furosoral
  • Lodisure (amlodipine)
  • Vetoryl (trilostane) Trilostane capsules and tablets for the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease and syndrome) in dogs. Available in multiple dosages (5mg, 10mg, 20mg, 30mg, 60mg, 120mg) and formulations including hard capsules and flavored tablets.
  • Diatrim (sulfadiazine/trimethoprim solution for injection) Sulfadiazine/trimethoprim solution for injection indicated for use in cattle, pigs, dogs, and cats.
  • Cyclo Spray (chlortetracycline topical spray) Chlortetracycline topical spray for superficial wound infections in livestock.
  • TAF Spray (thiamphenicol cutaneous spray) Thiamphenicol cutaneous spray for wound infections in animals.

Quantifiable outcome

  • Human Animal Bond Certified Company recognition in 2025
  • +1 more outcomes

Companies that use Dechra

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Dechra technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Dechra partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • IntervaccminorChannel Partner/ Reseller/ Distributor · 24 January 2025Intervacc received orders from Dechra Pharmaceuticals with an order value equivalent to approximately SEK 5.8 million, indicating a supply relationship.
  • Latham & Watkins LLPminorImplementation/ SI/ Consulting Partner · 19 July 2024Latham & Watkins advised Invetx in connection with its acquisition by Dechra Pharmaceuticals, providing legal advisory services for the $520 million transaction.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Dechra competitors and assessment

Company assessment

Direct peers

  • Virbac: France-based global veterinary pharmaceutical company, one of the top independent vet pharma specialists after Zoetis. Direct peer in companion animal specialty therapeutics, including in endocrinology (Vetoryl competitor in Cushing's) and dermatology.
  • Elanco Animal Health: Major US-listed animal health company (formerly Eli Lilly's animal health division, plus Bayer Animal Health acquisition). Competes head-to-head with Dechra in companion animal endocrinology, dermatology, and livestock therapeutics. Direct overlap in therapeutic areas and geographic channels.
  • Zoetis: The world's largest pure-play animal health company. Sells companion animal and livestock pharmaceuticals across endocrinology, dermatology, vaccines, and parasiticides. Direct competitor to Dechra across most therapeutic categories and the dominant benchmark for vet pharma economics.
  • Phibro Animal Health: US-listed animal health and nutrition company focused on livestock (poultry vaccines, nutritional specialty products, parasiticides) and select companion animal products. Most directly comparable on Dechra's food-producing animal side (poultry vaccines, cattle therapeutics).
  • Vetoquinol: Independent French veterinary pharmaceutical company competing in companion animal endocrinology (notably Prilactone/Trilostane in Cushing's disease) and dermatology. Direct head-to-head competitor to Dechra's Vetoryl franchise in key European markets.
  • Norbrook Laboratories: UK/Northern Ireland-based privately held veterinary pharmaceutical manufacturer. Comparable as a fellow non-US-headquartered vet pharma specialist operating in anti-infectives, parasiticides, and production animal therapeutics; competes with Dechra in European livestock channels.
  • Ceva Santé Animale: French global veterinary pharmaceutical company with strong positions in vaccines, companion animal therapeutics, and livestock. Direct competitor in food-producing animal segment (mastitis, vaccines, parasiticides) where Dechra also operates.

Others

  • IDEXX Laboratories: Leading veterinary diagnostics company rather than pharma, but operates in the same veterinary clinic channel and benefits from the same secular pet care tailwinds. Comparable unit economics and channel exposure make it the natural reference for the companion animal vet services ecosystem Dechra sells into, even though it doesn't directly compete on therapeutics.

Broad incumbents

  • Merck Animal Health (MSD): Animal health division of Merck/MSD, one of the largest global players in livestock vaccines and parasiticides. Overlaps with Dechra's food-producing animal segment while operating as a broader human-pharma-backed incumbent.
  • Boehringer Ingelheim Animal Health: Top-3 global animal health player owned by Boehringer Ingelheim (acquired Merial). Competes with Dechra across therapeutic areas and vaccines as part of a broader human-pharma-supported portfolio rather than as a pure-play specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Dechra social profiles

Digital presence

Dechra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dechra leadership team

Management profile

Number of profiles

Profiles1 record

Dechra subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Dechra funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dechra M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dechra

What does Dechra do?

Dechra develops, manufactures, and sells prescription and non-prescription veterinary pharmaceutical products across companion animals (dogs, cats), equine (horses), food-producing animals (cattle, pigs, poultry), and exotics. The portfolio spans therapeutic areas including endocrinology, anesthesia and analgesia, dermatology, anti-infectives, fluid therapy, nutrition, and vaccines. Dechra also provides the Dechra Academy eLearning platform offering free CPD modules and educational content to veterinary professionals.

Is Dechra a public or private company?

Dechra is a public company. It is classified as public and is currently operating.

When was Dechra founded?

Dechra was founded in 1997.

Where is Dechra based?

Dechra is headquartered in Shrewsbury, United Kingdom, in the Europe region.

How does Dechra make money?

One revenue line is on record: veterinary Pharmaceutical Products.

Who are Dechra's main competitors?

Direct peers on record are Virbac, Elanco Animal Health, Zoetis, Phibro Animal Health, Vetoquinol, Norbrook Laboratories and Ceva Santé Animale. IDEXX Laboratories is listed as an others. Broad incumbents are Merck Animal Health (MSD) and Boehringer Ingelheim Animal Health.

Does Dechra have an API?

No public API is recorded for Dechra.

What industry is Dechra in?

Dechra's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAG, Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid), with a secondary code of HLAMAEAH, Dermatology & Allergy Drugs. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceDechra Brings Laverdia® (verdinexor tablets), the First and Only FDA-Approved Oral Treatment for Dogs Diagnosed with LymphomaDechra announced Laverdia (verdinexor tablets), the first and only FDA-approved oral treatment for dogs with lymphoma, available for at-home use. The company noted that only about 20% of dogs with lymphoma receive chemotherapy, highlighting the unmet need. The treatment is available in multiple SKUs for different weight ranges.PR NewswireDechra Brings Laverdia® (verdinexor tablets), the First and Only FDA-Approved Oral Treatment for Dogs Diagnosed with LymphomaDechra announced the availability of Laverdia (verdinexor tablets), the first and only FDA-approved oral treatment for dogs with lymphoma. The company noted that only about 20% of dogs with lymphoma receive chemotherapy, highlighting an unmet need. The oral treatment can be used immediately after diagnosis, including for dogs not responding to standard therapy.Business Wire BlogDechra Brings Globally Trusted Domidine™ (detomidine hydrochloride) to the U.S. Equine MarketDechra announced the U.S. launch of Domidine, a detomidine hydrochloride sedative for horses. The product has been used globally for over a decade, with more than 7 million doses administered since 2016. It aims to provide a cost-effective option for equine sedation.Third NewsDechra's New Global Headquarters in Boston Enhances Community Engagement with $60,000 InvestmentDechra inaugurated its new global headquarters in Boston's Seaport District, marking a significant expansion of its North American presence. The company announced $60,000 in community investments through two strategic partnerships: a $50,000 grant to Pet Partners for animal-assisted therapy programs and a $10,000 donation to the Boston Police Foundation's Comfort Dog Program.PetageDechra Opens Global Headquarters in Boston, Invests in Local Community PartnershipsDechra opened its global headquarters in Boston's Seaport District, investing $60,000 in local community partnerships. The company announced collaborations with Pet Partners and the Boston Police Foundation, and commissioned a survey of 200 Boston residents on pet health and wellbeing.PR NewswireDechra Awards Nearly $80,000 in U.S. Charitable Donations Through Employee-Led Giving ProgramDechra, a global veterinary pharmaceuticals company, awarded nearly $80,000 in U.S. charitable donations through its employee-led Giving Committee program, with Heartland Therapeutic Riding and Muttville Senior Dog Rescue each receiving $10,000 as top recipients and 22 additional organizations receiving approximately $2,700 each. The program reflects Dechra's commitment to community giving and the human-animal bond, with employees nominating causes personally important to them. Over the past several years, Dechra has contributed more than $350,000 to nonprofit organizations across the U.S.PR NewswireDechra Announces FDA Approval of CosACTHen® (cosyntropin injection), the First and Only Cosyntropin Approved Specifically for Canine PatientsDechra announced FDA approval of CosACTHen® (cosyntropin injection) on May 19, 2026, making it the first and only cosyntropin specifically indicated for canine patients. The product is used for ACTH stimulation testing to evaluate adrenal function and aids in the diagnosis, confirmation, and monitoring of Cushing's Disease and Addison's Disease in dogs. The approval reinforces Dechra's commitment to veterinary endocrinology and provides veterinarians with an FDA-approved diagnostic tool for canine endocrine health.PetageDechra Announces FDA Approval of CosACTHen Cosyntropin Injection for Canine PatientsDechra announced FDA approval of CosACTHen, the first cosyntropin injection indicated for canine patients. The product is for evaluating adrenal function in dogs, supporting diagnosis and monitoring of Cushing's and Addison's disease. It is not for use in humans.BostonGlobe.comDechra, veterinary drug firm, moves headquarters to BostonDechra, a private equity-backed veterinary pharmaceuticals company, is relocating its global headquarters from Northwich, England, to Boston's Seaport District this summer. The move involves closing the company's US offices in Portland, Maine, Greensboro, N.C., and Kansas City, Kan., consolidating operations into a new 28,000-square-foot office at One Marina Park Drive. CEO Jesper Nordengaard said the relocation aims to position the company as a bridge between its European and American operations while advancing ambitions to become a major biotech player.AijournDechra to Establish Global Headquarters in Boston, Strengthening U.S. Leadership and Innovation PresenceDechra announced plans to relocate its global headquarters from Northwich, England, to Boston, Massachusetts, by June 2026, emphasizing its investment in the North American market and its focus on veterinary specialty care. The new Boston headquarters will serve as a strategic collaboration hub supporting a remote-first operating model and fostering innovation.